Publications by authors named "Vasyl Boyko"
Ther Adv Med Oncol
September 2024
Article Synopsis
- - The study aimed to assess the safety, tolerability, pharmacokinetics, and effectiveness of sasanlimab, a monoclonal antibody targeting PD-1, in treating participants with advanced cancers, including a focus on non-small-cell lung cancer.
- - An open-label design was used, with Phase Ib involving dose escalation and expansion in Asian participants, while Phase II included a global trial randomizing participants to receive either 300 mg every 4 weeks or 600 mg every 6 weeks.
- - Results indicated that Phase Ib had no dose-limiting toxicities and Phase II showed manageable grade 3 treatment-related adverse events, with confirmed response rates of 26.8% and 15.0%
